Movfor
Molnupiravir capsules for covid-19. It forces the virus to make copying errors so it cannot multiply.
- Category
- Antivirals
- Active ingredient
- Molnupiravir
- Route
- Oral use
- Form
- Capsule
- Strengths
- 200mg
Prescription and consultation requirements for Movfor vary by destination and are determined by the fulfilment partner.
Movfor details
- Condition
- Coronavirus Disease 2019 (COVID-19)
- Alternative names
- molnupiravir
- Therapeutic class
- Nucleoside Analog Antiviral
- Pharmacological class
- Antiviral Agent
- Contraindications
- pregnancy; hypersensitivity to molnupiravir
- Minor side effects
- diarrhoea; nausea; dizziness
- Moderate side effects
- headache; rash; vomiting
- Serious side effects
- anaphylaxis, requires immediate medical attention
- Dosage forms
- Capsule
- Administration route
- Oral use
- Supply category
- Prescription-only medicine (POM)
- Manufacturer
- Hetero Healthcare
- Onset Time
- 24–48 hours
- Duration
- 12 hours
- Storage instructions
- Store below 25°C.
- Age restrictions
- Approved for adults over eighteen years.
Patient summary
Molnupiravir capsules for covid-19. It forces the virus to make copying errors so it cannot multiply.
Mechanism of action
Incorporates into viral RNA, causing widespread replication errors that halt viral replication in tissues.
Pregnancy and breastfeeding
Pregnancy: High risk of fetal toxicity. Strictly contraindicated in pregnancy. Breastfeeding: Avoid.